FDA Balks At CIR Public-Private Partnership In FY 2017 Budget Request

Based on its fiscal 2017 budget justification, FDA does not support a congressional proposal to formalize Cosmetic Ingredient Review safety assessments through a public-private partnership. The agency still intends to prepare a report on the subject, as directed by Senate and House appropriations committees, but characterizes the proposed framework as "inappropriate."